{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:42:47Z","timestamp":1791499367835,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1CA186712"],"award-info":[{"award-number":["UM1CA186712"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Several bone-seeking radionuclides have been developed for palliation of metastatic bone pain since 1956, however, so far radium-223 dichloride is the first and only Food and Drug Administration (FDA) approved targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) based on ALSYMPCA phase 3 study. While radium-223 does improve pain and overall survival outcomes, the improvement can come at the expense of side effects such as bone marrow toxicity. The development of new and better treatment with long-standing pain relief is clearly an unmet medical need.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study is a non-randomized phase II study. The study population consists of 25 patients with CRPC who had progressed on any lines of prior therapies and whose serum testosterone level is less than 50\u00a0ng\/dl and have metastatic lesions to at least two bone sites, with at least one site that has clinically meaningful pain at baseline (\u2265\u20094 on an 11-point intensity scale). Eligible patients will be given two cycles of Sn-117\u00a0m-DTPA every 8\u00a0weeks or 56\u00a0days. Treatment will be administered by slow IV injection over 5\u201310\u00a0min. Retreatment after two cycles is allowed if patients meet the following retreatment criteria. The primary objective is to evaluate the efficacy of Sn-117\u00a0m-DTPA on sustained pain response in patients with CRPC metastatic to at least two bone sites and at least one with clinically meaningful pain at baseline (\u2265\u20094 on an 11-point pain intensity scale). Sustained pain response is defined as: 1) achieving pain index\u2009\u2264\u20093 within a 12-week period and 2) maintaining pain index\u2009\u2264\u20093 over a 16-week period. The secondary objectives are: safety and tolerability, measurement of Sn-117\u00a0m-DTPA activity by gamma-camera dosimetry scans, therapeutic efficacy, time to the first symptomatic skeletal event, duration of pain response, changes in PSA and ALP levels, patient-reported outcomes and progression free survival and overall survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Sn-117\u00a0m-DTPA is a unique bone-targeting theranostic radiopharmaceutical agent that selectively binds most heavily to bone metastases sites. This study will be the first prospective phase II trial to assess the pain efficacy and anti-tumor activity of Sn-117\u00a0m-DTPA in mCRPC with at least one clinically meaningful pain at baseline.<\/jats:p>\n                <jats:p>Trial registration.<\/jats:p>\n                <jats:p>ClincialTrials.gov Identifier: NCT04616547.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09496-2","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T12:02:54Z","timestamp":1650024174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A single arm phase II study of bone-targeted Sn-117\u00a0m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-4203","authenticated-orcid":false,"given":"Zin W.","family":"Myint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"El Khouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"9496_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4615-3398-6_18","volume":"324","author":"M Harada","year":"1992","unstructured":"Harada M, Iida M, Yamaguchi M, Shida K. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol. 1992;324:173\u201382.","journal-title":"Adv Exp Med Biol"},{"issue":"16","key":"9496_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2013.51.7219","volume":"32","author":"S Falk","year":"2014","unstructured":"Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol. 2014;32(16):1647\u201354.","journal-title":"J Clin Oncol"},{"issue":"6","key":"9496_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","volume":"5","author":"QN Nguyen","year":"2019","unstructured":"Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, et al. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019;5(6):872\u20138.","journal-title":"JAMA Oncol"},{"issue":"3","key":"9496_CR4","first-page":"185","volume":"16","author":"JH Lawrence","year":"1956","unstructured":"Lawrence JH, Tobias CA. Radioactive isotopes and nuclear radiations in the treatment of cancer. Cancer Res. 1956;16(3):185\u201393.","journal-title":"Cancer Res"},{"issue":"6","key":"9496_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0022-5347(17)59002-3","volume":"116","author":"N Firusian","year":"1976","unstructured":"Firusian N, Mellin P, Schmidt CG. Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol. 1976;116(6):764\u20138.","journal-title":"J Urol"},{"key":"9496_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.1965.03090070071032","volume":"193","author":"DP Joshi","year":"1965","unstructured":"Joshi DP, Seery WH, Goldberg LG, Goldman L. Evaluation of Phosphorus 32 for Intractable Pain Secondary to Prostatic Carcinoma Metastases. JAMA. 1965;193:621\u20133.","journal-title":"JAMA"},{"issue":"9","key":"9496_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF00254749","volume":"12","author":"GM Blake","year":"1986","unstructured":"Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12(9):447\u201354.","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"9496_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","volume":"25","author":"AT Porter","year":"1993","unstructured":"Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"9496_CR9","first-page":"1839","volume":"34","author":"C Collins","year":"1993","unstructured":"Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I\/II trial. J Nucl Med. 1993;34(11):1839\u201344.","journal-title":"J Nucl Med"},{"issue":"10","key":"9496_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0959-8049(97)00155-X","volume":"33","author":"I Resche","year":"1997","unstructured":"Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33(10):1583\u201391.","journal-title":"Eur J Cancer"},{"issue":"3B","key":"9496_CR11","first-page":"1773","volume":"17","author":"JM De Klerk","year":"1997","unstructured":"De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res. 1997;17(3B):1773\u20137.","journal-title":"Anticancer Res"},{"issue":"10","key":"9496_CR12","first-page":"1877","volume":"32","author":"HR Maxon 3rd","year":"1991","unstructured":"Maxon HR 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991;32(10):1877\u201381.","journal-title":"J Nucl Med"},{"issue":"3","key":"9496_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"9496_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","volume":"48","author":"S Nilsson","year":"2012","unstructured":"Nilsson S, Strang P, Aksnes AK, Franzen L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland OS. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678\u201386.","journal-title":"Eur J Cancer"},{"issue":"3","key":"9496_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0047-0740(85)90023-3","volume":"12","author":"SC Srivastava","year":"1985","unstructured":"Srivastava SC, Meinken GE, Richards P, Som P, Oster ZH, Atkins HL, Brill AB, Knapp FF Jr, Butler TA. The development and in-vivo behavior of tin containing radiopharmaceuticals--I. Chemistry, preparation, and biodistribution in small animals. Int J Nucl Med Biol. 1985;12(3):167\u201374.","journal-title":"Int J Nucl Med Biol"},{"issue":"7\u20138","key":"9496_CR16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.apradiso.2009.02.023","volume":"67","author":"B Ponsard","year":"2009","unstructured":"Ponsard B, Srivastava SC, Mausner LF, Russ Knapp FF, Garland MA, Mirzadeh S. Production of Sn-117m in the BR2 high-flux reactor. Appl Radiat Isot. 2009;67(7\u20138):1158\u201361.","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"9496_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0047-0740(85)90024-5","volume":"12","author":"ZH Oster","year":"1985","unstructured":"Oster ZH, Som P, Srivastava SC, Fairchild RG, Meinken GE, Tillman DY, Sacker DF, Richards P, Atkins HL, Brill AB, et al. The development and in-vivo behavior of tin containing radiopharmaceuticals--II. Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease. Int J Nucl Med Biol. 1985;12(3):175\u201384.","journal-title":"Int J Nucl Med Biol"},{"issue":"1","key":"9496_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1148\/radiology.186.1.7677974","volume":"186","author":"HL Atkins","year":"1993","unstructured":"Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Straub RF, Cabahug CJ, Weber DA, Wong CT, Sacker DF, Madajewicz S, et al. Biodistribution of Sn-117m(4+)DTPA for palliative therapy of painful osseous metastases. Radiology. 1993;186(1):279\u201383.","journal-title":"Radiology"},{"issue":"5","key":"9496_CR19","first-page":"725","volume":"36","author":"HL Atkins","year":"1995","unstructured":"Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D\u2019Alessandro T. Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med. 1995;36(5):725\u20139.","journal-title":"J Nucl Med"},{"issue":"2","key":"9496_CR20","first-page":"230","volume":"38","author":"GT Krishnamurthy","year":"1997","unstructured":"Krishnamurthy GT, Swailem FM, Srivastava SC, Atkins HL, Simpson LJ, Walsh TK, Ahmann FR, Meinken GE, Shah JH. Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med. 1997;38(2):230\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"9496_CR21","first-page":"61","volume":"4","author":"SC Srivastava","year":"1998","unstructured":"Srivastava SC, Atkins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G, Mausner LF, Swailem F, D\u2019Alessandro T, Cabahug CJ, et al. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I\/II clinical study. Clin Cancer Res. 1998;4(1):61\u20138.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09496-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09496-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09496-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T13:09:11Z","timestamp":1650114551000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09496-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9496"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09496-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This protocol has approved by the Ethics Committee of the Central Institutional Review Board Initiative for the National Cancer Institute. The CIRB complies with the Federal regulations 45 CFR 46, 21 CFR 50, and 21 CFR 56. If participants wish to take part in the study after they have been informed about the study procedures and meet eligibility criteria, they will be asked to sign an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"415"}}